1000 delegates from 30 countries are expected at BioTrinity making it one of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK.

Now in its 11th year, the aim of BioTrinity is to create an ideal networking and partnering platform for life science companies across the world to meet all under one roof and catalyse business in the industry, to ultimately help shape the future of healthcare.

BioTrinity offers unique access to global life science investors, big pharma executives and innovative CEOs of emerging R&D companies seeking to make deals and grow their networks.

Representatives of Selcia Drug Discovery and Selcia Radiochemistry will be available for meetings through the partnering system at BioTrinity.

For more information visit the BioTrinity conference website